IL1B and type 2 diabetes mellitus: CSF treatment alleviated metabolic dysfunction, promoted cognitive performance, and mitigated neuronal damage in T2DM mice, accompanied by the down-regulation of ROS, MDA, IL-1β, IL-6, as well as TNF-α and the elevation of SOD.